ClinicaliQ Trial Snapshot
- To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer — Recruiting • Phase II • Oncology • NCT07368998.
- What is being tested: Inavolisib (a PI3K inhibitor) combined with fulvestrant (an oestrogen receptor degrader) in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.
- Patient eligibility overview: Adults with advanced or metastatic breast cancer confirmed to have PIK3CA mutations, hormone receptor positivity, and HER2-negativity are eligible for enrolment in this trial.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of inavolisib in combination with fulvestrant compared with inavolisib in combination with fulvestrant in participants with PIK3CA-mutated, HR-positive, HER2-negative locally advanced or metastatic breast cancer (LA/mBC) in the post-cyclin-dependent kinase inhibitor (CDKi) setting.
Eligibility Snapshot
- : * Documented ER +/ HER2- tumor according to American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Disease progression after or during treatment with a combination of CDK4/6i and endocrine therapy: = 1 study-eligible PIK3CA mutation * Life expectancy of > 6 months * Ability, in the investigator's judgment, and willingness to comply with all study -related procedures, including completion of patient-reported outcomes
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.